Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of ISIS 301012 (Mipomersen) in Hypercholesterolemic Subjects on Stable Statin Therapy
NCT00231569Phase 2Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Sep 2005
- Primary completion
- Jun 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of mipomersen in hypercholesterolemia (7 cohorts), sponsored by Kastle Therapeutics LLC. Primary endpoint: Percent reduction in LDL-cholesterol from baseline. Started Sep 2005; status: completed.
02
Drugs
mipomersen
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00231569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231569.